The over- or under-inhibition of VEGF can be harmful, as evidenced by adverse effects such as proteinuria and glomerular thrombotic microangiopathy observed with anti-VEGF therapies like bevacizumab and ranibizumab. This evidence concerns the gene VEGFA and Genetic thrombotic microangiopathy.